• תמונה1
  • תמונה 2
  • תמונה 3
  • תמונה 4
  • תמונה 5
  • תמונה 6

Nanotechnology and Advanced Materials

Bar-Ilan's Institute of Nanotechnology and Advanced Materials (BINA) is a vibrant interdisciplinary research center with strong industry relations. Its globally trained faculty leads breakthrough research while preparing Israel’s next nanotech leaders. BINA offers companies access to top expertise, infrastructure, and collaborative R&D.

Find out what's going on
Bar Ilan's Institute of Nanotechnology and Advanced Materials (BINA)
Reactive Ion etcher Scientific Instrument
Advanced dry etchingHigh-density plasma etching system with independent control…
photonics Research Fields
Nanophotonics is a rapidly growing and interdisciplinary field that requires…
Prof. Doron Gerber Academic Staff

Viruses use very complex interaction networks to interface and hijack host machinery in order to do their bidding. Mapping protein interaction topologies represents a fundamental step towards understanding these biological processes. Over the last 3 years, I have developed quantitative high-throughput microfluidic tools and applied them to study protein interaction networks. These tools allow us to shed light on difficult biological questions with clinical implications. In many aspects, these questions could not be readily addressed with conventional methods (membrane protein expression, etc.). Viruses modulate host networks on the genometranscriptome and proteome levels. I would like to discover such viral-host interfaces by mapping viral protein interaction networks with the host genome, transcriptome and proteome. My research is guided by several questions: (1) What are the common "tools" viruses use to hijack host network? (2) How do these "tools" evolve? (3) How can we modulate or "turn off" these interfaces? (4) Can we mimic these "tools" in order to interface with cellular networks?  

A proof of concept of this methodology can be found in Einav and Gerber et al., 2008. In this paper, we used the same microfluidic platform to characterize a new function for a membrane protein from Hepatitis C virus, as well as find inhibitors to this new function. In less than 2 years, we now already have a compound that successfully passed preliminary clinical trials.